Phibro Animal Health earnings date
Phibro Animal Health (PB8) Q1 2027 Earnings Report
DE:PB8 Q1 2027 EPS Results
- Actual EPS
- EUR 0.72
- Consensus EPS
- EUR 0.71
- Beat/Miss
- Beat by +EUR 0.01
- One Year Ago EPS
- EUR 0.66
DE:PB8 Q1 2027 Revenue Results
- Actual Revenue
- EUR 350.86M
- Expected Revenue
- EUR 346.91M
- Beat/Miss
- Beat by +EUR 3.95M
- YoY Revenue Growth
- +6.29%
Earnings Announcement Details
- Quarter
- Q1 2027
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Phibro Animal Health's next earnings date is estimated for February 10, 2027, based on past reporting schedules.
Q1 2027 Earnings Call Audio
Q1 2027 Earnings Slide Deck
Q1 2027 Earnings Call Summary
The call was broadly positive: the company delivered 6% sales growth, 4% adjusted EBITDA growth, stronger net income, significant growth in Mineral Nutrition and Performance Products, positive cash flow, and maintained full-year guidance. These results were partially offset by weaker poultry-related demand, a 1% decline in Animal Health adjusted EBITDA, a $5.2 million Virginiamycin decline in Brazil, elevated inventory, higher SG&A and ongoing pressure on protein-producer profitability.
For fiscal 2027, Phibro maintained guidance for net sales of $1.5 billion to $1.6 billion, also stated as $1.550 billion to $1.6 billion, representing growth of 2% to 5% and a midpoint of approximately 4%; total adjusted EBITDA of $258 million to $268 million, representing growth of 1% to 5% and a midpoint of approximately 3%; adjusted diluted EPS of $3.41 to $3.59; and adjusted net income of $140 million to $147 million, representing growth of 6% to 11% and a midpoint of approximately 9%. The adjusted effective income tax rate is estimated at approximately 20% and includes the benefit of the resolution of foreign tax audit expected in the future quarter, while the company expects it to be higher in fiscal year 2028. Nutritional specialties and vaccines are forecast to grow in the mid- to high single digits for the year, with no further Virginiamycin sales in Brazil built into this year's numbers; GAAP net income and EPS assume constant currency and no additional gains or losses from FX movements, and revenue growth is expected to be higher than EBITDA growth in Q2.
- Quarterly Sales and Adjusted EBITDA GrowthFiscal 2027 first-quarter sales grew 6% to $386.8 million and adjusted EBITDA increased 4% to $64.3 million, despite a tough comparison with a very strong first quarter a year ago.
- Net Income ImprovementGAAP net income increased $3 million, or approximately 11%, to $29.5 million from $26.5 million in the prior-year quarter. Adjusted net income increased $2.5 million to $32.4 million.
- Strong Mineral Nutrition PerformanceMineral Nutrition sales increased 17% to $73.6 million, driven by higher demand and average selling prices for zinc oxide, copper and trace minerals. Adjusted EBITDA increased $1.6 million.
- Mineral Nutrition Strategic PositioningThe company said it has been shifting Mineral Nutrition toward higher-margin, faster-growing markets, including plant nutrition, dairy and pet food, supported by investments in talent, facilities and processes. Management expects continued growth in these areas.
- Performance Products GrowthPerformance Products sales increased 16% to $20.2 million, driven by higher demand for copper-based and fluoride products. Adjusted EBITDA increased $1.2 million.
- Growth in MFAs and Ethanol Processing AidsAnimal Health MFA and other sales increased 6%, supported by demand in North America and Asia and continued growth in ethanol processing aids. The Zoetis portfolio was a major contributor to MFA growth, while the ethanol performance group delivered strong results.
- Animal Health Sales GrowthAnimal Health sales increased 3% to $293 million, in line with the company's plan. Management said the number of birds being raised remains healthy and that underlying chicken demand is present.
- Full-Year Guidance MaintainedManagement maintained fiscal 2027 guidance for net sales of $1.5 billion to $1.6 billion, adjusted EBITDA of $258 million to $268 million and adjusted diluted EPS of $3.41 to $3.59. The detailed guidance presentation specified net sales of $1.550 billion to $1.6 billion, representing 2% to 5% growth, adjusted EBITDA growth of 1% to 5%, and adjusted net income of $140 million to $147 million, representing 6% to 11% growth.
- Positive Cash Flow and Capital PositionThe company generated $22 million of positive free cash flow for the 12 months ended September 30, 2026, including $86 million of operating cash flow and $64 million of capital expenditures. Cash and short-term investments were $83 million at quarter-end.
- Leverage and Shareholder Return MetricsGross leverage was 2.9x based on $740 million of total debt and $257 million of trailing 12-month adjusted EBITDA. Net leverage was 2.6x based on $656 million of net debt and $257 million of trailing 12-month adjusted EBITDA. The company paid a quarterly dividend of $0.12 per share, or $4.9 million in aggregate.
- Chicago Heights Closure on ScheduleThe closure of the Chicago Heights plant remains on schedule, with production expected to wind down in summer and early fall 2027. Products are expected to move to other Phibro plants and contract manufacturers.
- Improving Feed Cost OutlookManagement said cash corn prices declined from about $5.50 per bushel over the prior five weeks to under $4.50, reducing feed cost by approximately $1 per bushel. Higher corn inventories and yields were also cited as factors that should support livestock-production affordability as 2026 ends and 2027 begins.
- Additional Cattle Supply ExpectedThree ports are currently open for live Mexican cattle imports, averaging about 700 animals per day. Imports are projected at 200,000 head in 2026 and just over 1 million head in 2027. Beef-on-dairy supply was also cited at approximately 5.5 million head, or about 20% of the roughly 27 million head fed for slaughter annually.
- Expected Recovery in Poultry Product LinesManagement expects the pullback in poultry purchases to normalize over fiscal 2027 and maintained its forecast for Nutritional Specialties and Vaccines to grow in the mid- to high single digits for the full year.
DE:PB8 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 10, 2027 | 2027 (Q2) | 0.85- | 0.79 | ― | ― |
| Nov 04, 2026 | 2027 (Q1) | 0.710.72 | 0.66 | 8.22% (+0.05) | |
| Aug 26, 2026 | 2026 (Q4) | 0.650.77 | 0.52 | 49.12% (+0.25) | |
| May 06, 2026 | 2026 (Q3) | 0.650.69 | 0.57 | 20.63% (+0.12) | |
| Feb 04, 2026 | 2026 (Q2) | 0.610.79 | 0.49 | 61.11% (+0.30) | |
| Nov 05, 2025 | 2026 (Q1) | 0.560.66 | 0.32 | 108.57% (+0.34) | |
| Aug 27, 2025 | 2025 (Q4) | 0.470.52 | 0.37 | 39.02% (+0.15) | |
| May 07, 2025 | 2025 (Q3) | 0.470.57 | 0.28 | 103.23% (+0.29) | |
| Feb 05, 2025 | 2025 (Q2) | 0.390.49 | 0.3 | 63.64% (+0.19) | |
| Nov 06, 2024 | 2025 (Q1) | 0.220.32 | 0.13 | 150.00% (+0.19) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


